Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
166 hedge funds and large institutions have $1.97B invested in Acceleron Pharma in 2019 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 61 increasing their positions, 46 reducing their positions, and 25 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
33% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 46
5% less call options, than puts
Call options by funds: $5.8M | Put options by funds: $6.14M
3% less funds holding
Funds holding: 171 → 166 (-5)
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
14% less capital invested
Capital invested by funds: $2.3B → $1.97B (-$323M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$15.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.5M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$9.98M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$8.05M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$38M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.9M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$13.3M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$12.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$12.2M |
XLRN Hedge Fund Activity: Q2 2019 in Review
166 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q2 2019, worth a combined $1.97B — down 14% from $2.3B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of XLRN and 22 opened new positions — a net loss of 3 holders — while 46 trimmed existing stakes and 61 added.
The largest buyer was Great Point Partners, adding an estimated $15.3M. The largest seller was Fidelity Investments, cutting an estimated $38M.
- 166 institutional investors held Acceleron Pharma (XLRN) as of Q2 2019, down from 171 in Q1 2019.
- Funds reported $1.97B of Acceleron Pharma stock for Q2 2019, down 14% quarter-over-quarter.
- 22 funds opened new Acceleron Pharma positions in Q2 2019 and 25 closed out, a net change of -3 holders.
- The largest Acceleron Pharma buyer in Q2 2019 was Great Point Partners, an estimated $15.3M added.
- The largest Acceleron Pharma seller in Q2 2019 was Fidelity Investments, an estimated $38M sold.
Based on aggregated 13F filings for Q2 2019.